Navigation Links
Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism
Date:2/24/2010

OMAHA, Neb., Feb. 24 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder.  Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010.  Financial terms of the agreement were not disclosed.

"We are pleased to have the opportunity to develop and offer a genetic test to clinicians and parents that will assist in the evaluation of children who are thought to be at high risk of being autistic," stated '/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Transgenomic Presents at 12th Annual BIO CEO & Investor Conference
2. Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit
3. Transgenomic, Inc. Reports Third Quarter 2009 Results
4. Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinsons Disease
5. Transgenomic, Inc. Reports Second Quarter 2009 Results
6. Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
7. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
8. Transgenomic, Inc. Announces Appointment of New Board Members
9. Transgenomic, Inc. Reports First Quarter 2009 Results
10. Reminder: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
11. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... York , May 21, 2013 ... Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products and ... IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and ... billion in 2011 and is expected to grow at ... reach an estimated value of USD 4.7 billion in ...
(Date:5/21/2013)... 21, 2013 Many have long discussed ... to acne. Recently physicians from Clinical Psychiatry.com ... on the skin, and suggested using hypnotherapy ... chemicals produced from stress that cause acne. , Doctors ... feelings acne brings about, stress causes changes in the ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
(Date:5/21/2013)... May 21, 2013  Personal Genome Diagnostics Inc. ... proprietary methodologies and expertise in genomic analysis of ... in collaboration with Blueprint Medicines.  PGDx is an ... genomic alterations in tumors, and Blueprint Medicines is ... for a genetically defined patient population. ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3
... Patients Approved by the FDA since 2001 -, ... announced that the U.S. Food and Drug Administration (FDA) ... patients with chronic lymphocytic leukemia (CLL), a slowly,progressing blood ... more than 15,000 new cases of this rare disease ...
... March 20 Lentigen Corporation today,announced an exclusive ... Cleveland, Ohio, to develop a novel stem-cell therapy,for ... the agreement,Case Western and its primary affiliate, University ... vivo clinical trial, and Lentigen will be,responsible for ...
... Biologically active tissue adhesive allows for placement of skin grafts ... ... 20 Baxter Healthcare,Corporation announced today the U.S. Food and ... and only,slow-setting fibrin sealant indicated for use in adhering skin ...
Cached Biology Technology:Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 2Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 3Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 4Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia 5Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer 2Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer 3Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients 2Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients 3
(Date:5/21/2013)... Society (ACS), the world,s largest scientific society, invites ... & Exposition, September 8-12, 2013, in Indianapolis, Ind. ... Center and at area hotels. , With more ... science,s horizons from astronomy to zoology ― ... journalists a rich assortment of spot news and ...
(Date:5/21/2013)... The largest gathering of biomass experts , ... , When? 03-07 June 2013 ... scientific research, resource assessment, market and policy developments, manufacturing ... the world and benefiting from its 2013 edition from ... more than 60 countries, more than 240 plenary and ...
(Date:5/21/2013)... 2013 Royal Philips Electronics (NYSE: PHG, AEX: ... portable ultrasound with Philips, industry leading Live 3D TEE, ... xMATRIX with available Live 3D TEE and ICE will ... the EuroPCR, official meeting for the European Association of ... its launch in 2012, Philips CX50 xMATRIX has been ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
... University researchers are calling on policymakers to encourage the transition ... gas through a carbon tax. Such a mechanism would ... United Nations Climate Change Conference in Copenhagen last December, the ... 2 emissions by 17 percent by 2020. ...
... 2010 It,s safe to say that cilia, the hairlike ... cells, have long been misunderstood underestimated, even. Not ... sperm, one type of cilia has been known to serve ... supporting a crowd-surfer.) But for decades another type of cilia, ...
... New findings reported in the July issue of Cell ... as to why some people might suffer from high levels ... and cardiovascular disease. They can also lead to inflammation of ... Loren Fong and Stephen Young of the University of California, ...
Cached Biology News:Researchers calculate the cost of CO2 emissions, call for carbon tax 2Researchers demystifying complex cellular communications hubs found in sensory neurons 2Researchers demystifying complex cellular communications hubs found in sensory neurons 3Study sheds light on triglyceride metabolism 2
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
... The MEGAscript RNAi Kit is ... large mass amounts of ready-to-use ... non-mammalian systems. The MEGAscript RNAi ... patented high-yield transcription technol-ogy and ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... as building blocks, Parker can create ... solutions that are ideal for pick-and-place ... ,system, Parker can also integrate pneumatic ... and ,guarding., Standard or custom ...
Biology Products: